Hyperphosphorylated tau contributes to synaptic damage and neuronal dysfunction in neurodegenerative diseases such as Alzheimer’s disease (AD), making it a key therapeutic target. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.